Arcellx Inc (ACLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcellx Inc (ACLX) has a cash flow conversion efficiency ratio of -0.145x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.17 Million) by net assets ($402.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ACLX equity to assets ratio to measure how much of total assets are equity-financed.
Arcellx Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Arcellx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Arcellx Inc (ACLX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Arcellx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcellx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CIG ShangHai Co Ltd Class A
SHG:603083
|
-0.026x |
|
Gaztransport & Technigaz SAS
PA:GTT
|
0.372x |
|
Maha Properti Indonesia Tbk PT
JK:MPRO
|
-0.003x |
|
Klarna Group plc
NYSE:KLAR
|
0.180x |
|
DB Insurance Co Ltd
KO:005830
|
-0.197x |
|
Smith AO Corporation
NYSE:AOS
|
0.138x |
|
Grupo Financiero Galicia S.A
F:GF4
|
-0.138x |
|
VF Corporation
NYSE:VFC
|
0.012x |
Annual Cash Flow Conversion Efficiency for Arcellx Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Arcellx Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Arcellx Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $402.35 Million | $-210.26 Million | -0.523x | -184.74% |
| 2024-12-31 | $454.79 Million | $-83.47 Million | -0.184x | -142.92% |
| 2023-12-31 | $485.38 Million | $207.57 Million | 0.428x | +188.26% |
| 2022-12-31 | $204.95 Million | $-99.30 Million | -0.485x | -208.55% |
| 2021-12-31 | $-121.52 Million | $-54.24 Million | 0.446x | +178.71% |
| 2020-12-31 | $50.54 Million | $-28.66 Million | -0.567x | -198.90% |
| 2019-12-31 | $-32.74 Million | $-18.77 Million | 0.573x | +216.97% |
| 2018-12-31 | $14.00 Million | $-6.86 Million | -0.490x | -- |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more